LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
106.00
-2.18 (-2.02%)
As of 2:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close108.18
Open107.51
Bid105.85 x 1000
Ask105.97 x 900
Day's Range104.02 - 108.14
52 Week Range84.45 - 202.45
Volume132,111
Avg. Volume424,233
Market Cap2.015B
Beta (3Y Monthly)1.57
PE Ratio (TTM)3.47
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-07-02
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

    Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.

  • CNW Group

    ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.

  • GlobeNewswire

    Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.

  • PR Newswire

    Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP

    Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27 percent net return in 1H, 2019 SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, ...

  • Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
    PR Newswire

    Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

    SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.

  • Business Wire

    Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

    Ligand Pharmaceuticals Incorporated (LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has identified and validated the target using its next-generation SITESEEKER® phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.

  • Business Wire

    Ligand Licenses VER250840 to Cumulus Oncology

    Ligand Pharmaceuticals Incorporated (LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in the mid-to-high single digit range, depending on revenue. In addition, Ligand is eligible to receive an additional fee, payable in cash or Cumulus equity, upon Cumulus achieving specified financing-related events.

  • Business Wire

    Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

    Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all expenses to develop or commercialize SB206, and will use 100% of the proceeds from this transaction in the development and pursuit of regulatory approval for SB206.

  • GlobeNewswire

    Novan Completes Funding Transaction with Ligand Pharmaceuticals

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.

  • Business Wire

    Ligand Reports First Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today

  • Business Wire

    Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Ligand Pharmaceuticals Incorporated (LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.

  • Business Wire

    Ligand to Report First Quarter 2019 Results on May 2nd

    Ligand Pharmaceuticals Incorporated announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Business Wire

    Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection

    Ligand Pharmaceuticals Incorporated (LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of Sage Therapeutics’ (SAGE) ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. PPD can affect women during pregnancy or after childbirth.

  • Business Wire

    Ligand to Participate in Four Upcoming Investor Conferences

    Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences:

  • Business Wire

    Ligand Provides Highlights from Today’s Analyst Day Event

    At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (LGND) reviewed the recent progress of its business and financial growth outlook. Management provided additional details on its 2019 financial guidance and a preliminary financial outlook for 2020, discussed its technology platforms, including the opportunity and importance of its OmniAb technology platform. Ligand leverages its diversification with Shots on Goal, which are programs fully-funded by partners and backed by Ligand’s patents, know-how and/or data.

  • GlobeNewswire

    Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

    COLUMBUS, Ohio, March 11, 2019 -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific.

  • Business Wire

    Ligand Sells Promacta Assets and Royalty for $827 Million

    Ligand Pharmaceuticals Incorporated (LGND) and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash. Promacta (eltrombopag) is known as Revolade® outside the U.S. and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019.